GAIN THERAPEUTICS, INC (GANX) Return on equity 2021–2024
GAIN THERAPEUTICS, INC (GANX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-162.3%FY2024 · since FY2021: -224.0% → -162.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -162.3% | -44.3 pp |
| FY2023 | -117.9% | -67.4 pp |
| FY2022 | -50.5% | +173.4 pp |
| FY2021 | -224.0% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More GANX financial trends
GANX RevenueGANX Net incomeGANX Net marginGANX Gross profitGANX Gross marginGANX Operating incomeGANX Operating marginGANX Operating cash flowGANX Free cash flowGANX Capital expendituresGANX Stock buybacksGANX Dividends paidGANX Total assetsGANX Total liabilitiesGANX Shareholders’ equityGANX overview →